For research use only.
| Synonyms | IL1F, MVCD, IL1RN, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3, IL1F3, IL1RA, IRAP, MVCD4, Anakinra, IL1 inhibitor, Interleukin-1 receptor antagonist protein, F630041P17Rik, ICIL 1RA, ICIL1RA, IL1RN (IL1F3), Interleukin 1 receptor antagonist, Intracellular IL 1 receptor antagonist type II, Intracellular interleukin 1 receptor antagonist (icIL 1ra), MGC10430, Type II interleukin 1 receptor antagonist |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Arg 26-Glu 177 |
| Accession | NP_776214.1 |
| Calculated Molecular Weight | 17.3 kDa |
| Observed Molecular Weight | 17.3 kDa |
| Tag | None |
| Bio-activity | 1. Immobilized human IL1RA at 10 μg/ml (100 μl/well) can bind human IL1R2-Fc, The EC50 of human IL1R2-Fc is 0.04-0.1 μg/mL. 2. Immobilized human IL1RA at 10 μg/ml (100 μl/well) can bind human IL1R1-Fc, The EC50 of human IL1R1-Fc is 0.08-0.2 μg/mL. 3. Measured by its ability to induce Interferon gamma secretion by human natural killer lymphoma NK-92 cells in the presence of 250pg/mL IL1a. The EC50 for this effect is typically 3-12 ng/mL. |
| Purity | > 97 % as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation |
Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
| Background | Interleukin-1 receptor antagonist (IL-1RA) also known as IL1RN is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1; alpha (IL1A) and interleukin 1; beta (IL1B); and modulates a variety of interleukin 1 related immune and inflammatory responses. A polymorphism of this protein encoding gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer. IL-1RA/IL1RN may inhibit the activity of IL-1 by binding to its receptor and it has no IL-1 like activity. Genetic variation in IL-1RA/IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy; diabetic nephropathy leading to end-stage renal disease; and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Defects in IL-1RA/IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) which is also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection; high-titer autoantibodies; or autoreactive T-cells. DIRA is a rare; autosomal recessive; genetic autoinflammatory disease that results in sterile multifocal osteomyelitis; and pustulosis from birth. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
{{item.title}}
IF：{{item.impact}}
Journal：{{item.journal}}
DOI：{{item.doi}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
{{item.content}}
